Edition:
United Kingdom

Oasmia Pharmaceutical AB (OASM.OQ)

OASM.OQ on NASDAQ Stock Exchange Capital Market

0.97USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.97
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,908
52-wk High
$3.70
52-wk Low
$0.80

Chart for

About

Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company engaged in the field of human and veterinary oncology. The Company’s activities are divided into two segments: Human Health and Animal Health. The Human Health segment specializes in ovarian and breast cancer. The Animal Health area focuses on developing cancer... (more)
No analyst recommendations are available for .

Overall

Beta: 1.50
Market Cap(Mil.): kr478.06
Shares Outstanding(Mil.): 176.41
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Oasmia receives marketing approval for Paclical in Kazakhstan

* OASMIA PHARMACEUTICAL RECEIVES MARKETING APPROVAL FOR PACLICAL® IN KAZAKHSTAN Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

11 Dec 2017

BRIEF-Oasmia Pharmaceutical Q2 operating loss shrinks

* OASMIA PHARMACEUTICAL AB Q2 ‍CONSOLIDATED NET SALES AMOUNTED TO TSEK 1,651 COMPARED TO TSEK 56 IN THE SECOND QUARTER THE PREVIOUS YEAR ​

01 Dec 2017

BRIEF-Oasmia completes 28 mln SEK private placement of new convertible instruments

* OASMIA HAS COMPLETED A PRIVATE PLACEMENT OF NEW CONVERTIBLE INSTRUMENTS IN A TOTAL AMOUNT OF SEK 28,000,000

30 Nov 2017

BRIEF-Oasmia CFO resigns

* Oasmia Pharmaceutical Ab Announces Resignation Of Its Chief Financial Officer

04 Oct 2017

BRIEF-Nexttobe extends loan to Oasmia Pharmaceutical

* Nexttobe extends loan to Oasmia Pharmaceutical Further company coverage: (Reporting by Stockholm Newsroom)

02 Oct 2017

BRIEF-Oasmia Q1 operating loss lower

* Says Q1 operating loss was TSEK 28,421 compared to TSEK 32,343 in Q1 previous year

01 Sep 2017

BRIEF-Oasmia Pharmaceutical says receives market approval for anti-cancer drug in Russia

* Receives Market Approval For Its Anti-cancer Drug Doxophos® in Russia Source text for Eikon: Further company coverage: (Reporting By Johan Sennero)

08 Aug 2017

BRIEF-Oasmia Pharmaceutical says through rights issue, its share capital up by 5 mln SEK to 17.6 mln SEK

* Says through rights issue, Oasmia's share capital increases by sek 5 million to sek 17.6 million

07 Jul 2017

Earnings vs. Estimates